Article Text

other Versions

PDF
Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial
  1. D van der Heijde (manuscripts{at}jkmed.com)
  1. Leiden University Medical Center
    1. M H Schiff (mschiff{at}denverarthritisclinic.com)
    1. University of Denver
      1. J Sieper (joachim.sieper{at}charite.de)
      1. University Clinic Benjamin Franklin
        1. A Kivitz (akivitz{at}prodigy.net)
        1. Altoona Center for Clinical Research
          1. R L Wong (robert.wong{at}abbott.com)
          1. Abbott Laboratories
            1. H Kupper (hartmut.kupper{at}abbott.com)
            1. Abbott GmbH & Co. KG
              1. B A C Dijkmans (bac.dijkmans{at}vumc.nl)
              1. VU University Medical Center and the Jan van Breemen Institute
                1. P J Mease (pmease{at}nwlink.com)
                1. Seattle Rheumatology Associates
                  1. J C Davis, Jr. (jcdjr{at}sbcglobal.net)
                  1. UCSF

                    Abstract

                    Objective: To determine the long-term effect of adalimumab on patients with ankylosing spondylitis (AS) who participated in Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS (ATLAS), a randomised, double-blind, placebo-controlled, 24-week trial.

                    Methods: Patients received adalimumab 40 mg every other week (eow) or placebo for 24 weeks in ATLAS. At Week 24, patients were switched to open-label adalimumab 40 mg eow. Efficacy measures included 20% improvement in the Assessment in SpondyloArthritis international Society (ASAS) criteria (ASAS20), ASAS40, and ASAS partial remission responses and changes in individual components of the ASAS20 response evaluations, for example, Bath AS Functional Index (BASFI) and Bath AS Disease Activity Index (BASDAI). Two-year interim data were analysed based on the total duration of adalimumab exposure, irrespective of treatment randomization group.

                    Results: At Year 2, 255 (82.0%) of the original 311 ATLAS patients continued receiving adalimumab treatment. Improvements in ASAS responses observed in ATLAS were sustained during long-term treatment; 64.5% (200/310) were ASAS20 responders, 50.6% (157/310) were ASAS40 responders, and 33.5% (104/310) had maintained ASAS-defined partial remission. Changes in individual ASAS response components were sustained or improved during long-term adalimumab treatment. From ATLAS baseline to Year 2, respectively, BASDAI improved from 6.3±1.7 to 2.4±2.3 and BASFI improved from 5.2±2.4 to 2.9±2.5. Adalimumab was well-tolerated. No cases of tuberculosis, congestive heart failure, lupus-like symptoms, or demyelinating disease were reported.

                    Conclusions: Adalimumab reduced the signs and symptoms of AS and induced partial remission for up to 2 years. The long-term safety profile was similar to the short-term safety profile.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.